HZNP, just read CC transcript-
I have no idea why this stock went down today after beating Q3 estimates by 15%, and raising guidance for the year. All I know is, a rare disease drug company, which has patents well into 2030s on 3 major drugs, with revenues of $3B+/year, and a monopoly on the largest revenue drug, with growth expected of 30%/year for the next 3-5 years is super cheap at a PE of 17 going forward. This not to mention another 6-7 drugs they have which bring in $1B+/year as well.
It amazes me that I am the only one on this board in this stock.
